Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cascadian Therapeutics Inc (NASDAQ:CASC)

0.9431
Delayed Data
As of Jun 30
 -0.0511 / -5.14%
Today’s Change
0.82
Today|||52-Week Range
4.02
-57.52%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$129.2M

Company Description

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Its current clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The company was founded on September 7, 2007 and is headquartered in Seattle, WA.

Contact Information

Cascadian Therapeutics, Inc.
2601 4th Avenue
Seattle Washington 98121
P:(206) 801-2100
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Scott D. MyersPresident, Chief Executive Officer & Director
Gary W. ChristiansonChief Operating Officer
Julia Marie EastlandCFO, Secretary & VP-Corporate Development
Scott Robert PetersonChief Scientific Officer
Guy F. CiprianiVice President-Business Development